Aptevo Therapeutics Inc. (APVO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAPVO / S&P 3.98% / 15.20% |
LoseAPVO / S&P APVO unavailable / 15.00% |
LoseAPVO / S&P -99.70% / 50.40% |
| 2026-Q10/3 |
LoseAPVO / S&P -54.72% / -4.33% |
LoseAPVO / S&P APVO unavailable / 11.30% |
LoseAPVO / S&P -99.24% / 27.70% |
| 2025-Q40/3 |
LoseAPVO / S&P -63.87% / 2.65% |
LoseAPVO / S&P APVO unavailable / 9.00% |
LoseAPVO / S&P -93.90% / 13.40% |
| 2025-Q31/3 |
LoseAPVO / S&P -52.46% / 8.12% |
LoseAPVO / S&P APVO unavailable / 4.61% |
WinAPVO / S&P 598.11% / 13.45% |
| 2025-Q21/3 |
LoseAPVO / S&P -86.85% / 10.94% |
LoseAPVO / S&P APVO unavailable / 4.83% |
WinAPVO / S&P 667.54% / 10.63% |
| 2025-Q11/3 |
LoseAPVO / S&P -73.09% / -4.27% |
LoseAPVO / S&P APVO unavailable / 4.98% |
WinAPVO / S&P 1043.36% / 10.57% |
| 2024-Q41/3 |
LoseAPVO / S&P -35.29% / 2.41% |
LoseAPVO / S&P APVO unavailable / 5.25% |
WinAPVO / S&P 1181.12% / 6.15% |
| 2024-Q31/3 |
LoseAPVO / S&P -41.18% / 5.89% |
LoseAPVO / S&P APVO unavailable / 5.89% |
WinAPVO / S&P 6977.14% / 6.11% |
| 2024-Q21/3 |
LoseAPVO / S&P -93.48% / 4.28% |
LoseAPVO / S&P APVO unavailable / 5.38% |
WinAPVO / S&P 9863.97% / 5.12% |
| 2024-Q10/3 |
LoseAPVO / S&P -41.11% / 10.56% |
LoseAPVO / S&P APVO unavailable / 5.71% |
LoseAPVO / S&P -13288.35% / 5.59% |
| 2023-Q40/3 |
LoseAPVO / S&P -45.15% / 11.69% |
LoseAPVO / S&P APVO unavailable / 6.81% |
LoseAPVO / S&P -146893.67% / 7.78% |
| 2023-Q30/3 |
LoseAPVO / S&P -77.40% / -3.27% |
LoseAPVO / S&P APVO unavailable / 7.52% |
LoseAPVO / S&P -4836.51% / -5.03% |
| 2023-Q20/3 |
LoseAPVO / S&P -28.26% / 8.74% |
LoseAPVO / S&P APVO unavailable / 9.50% |
LoseAPVO / S&P -3033.83% / -8.57% |
| 2023-Q10/3 |
LoseAPVO / S&P -12.28% / 7.50% |
LoseAPVO / S&P APVO unavailable / 10.77% |
LoseAPVO / S&P -441.83% / -15.69% |
| 2022-Q40/3 |
LoseAPVO / S&P -23.68% / 7.56% |
LoseAPVO / S&P APVO unavailable / 11.88% |
LoseAPVO / S&P APVO unavailable / -17.99% |
| 2022-Q30/3 |
LoseAPVO / S&P -15.08% / -4.88% |
LoseAPVO / S&P APVO unavailable / 13.47% |
LoseAPVO / S&P APVO unavailable / -1.41% |
| 2022-Q20/3 |
LoseAPVO / S&P -39.01% / -16.10% |
LoseAPVO / S&P APVO unavailable / 13.71% |
LoseAPVO / S&P APVO unavailable / 11.04% |
| 2022-Q11/3 |
LoseAPVO / S&P -25.41% / -4.60% |
WinAPVO / S&P 92.94% / 15.97% |
LoseAPVO / S&P APVO unavailable / 42.23% |
| 2021-Q40/3 |
LoseAPVO / S&P -49.03% / 11.03% |
LoseAPVO / S&P APVO unavailable / 15.00% |
LoseAPVO / S&P APVO unavailable / 96.40% |
| 2021-Q30/3 |
LoseAPVO / S&P -31.16% / 0.58% |
LoseAPVO / S&P APVO unavailable / 10.77% |
LoseAPVO / S&P APVO unavailable / 69.42% |
| 2021-Q20/3 |
LoseAPVO / S&P -26.51% / 8.55% |
LoseAPVO / S&P APVO unavailable / 6.58% |
LoseAPVO / S&P APVO unavailable / 51.81% |
| 2021-Q10/3 |
LoseAPVO / S&P -16.73% / 6.17% |
LoseAPVO / S&P APVO unavailable / -1.06% |
LoseAPVO / S&P APVO unavailable / 7.39% |
| 2020-Q41/3 |
WinAPVO / S&P 382.24% / 12.15% |
LoseAPVO / S&P APVO unavailable / -3.72% |
LoseAPVO / S&P APVO unavailable / -33.42% |
| 2020-Q30/3 |
LoseAPVO / S&P -8.98% / 8.93% |
LoseAPVO / S&P APVO unavailable / -2.04% |
LoseAPVO / S&P APVO unavailable / -27.10% |
| 2020-Q21/3 |
WinAPVO / S&P 125.68% / 20.54% |
LoseAPVO / S&P APVO unavailable / -0.46% |
LoseAPVO / S&P APVO unavailable / -27.11% |
| 2020-Q10/3 |
LoseAPVO / S&P -59.65% / -19.60% |
LoseAPVO / S&P APVO unavailable / 3.47% |
LoseAPVO / S&P APVO unavailable / -14.75% |
| 2019-Q42/3 |
WinAPVO / S&P 11.39% / 9.07% |
WinAPVO / S&P 40.56% / 5.36% |
LoseAPVO / S&P APVO unavailable / 2.99% |
| 2019-Q31/3 |
LoseAPVO / S&P -33.71% / 1.70% |
WinAPVO / S&P 52.20% / 5.02% |
LoseAPVO / S&P APVO unavailable / 0.21% |
| 2019-Q21/3 |
LoseAPVO / S&P -1.44% / 4.30% |
WinAPVO / S&P 33.51% / 6.64% |
LoseAPVO / S&P APVO unavailable / 8.65% |
| 2019-Q11/3 |
LoseAPVO / S&P -29.13% / 13.65% |
WinAPVO / S&P 56.86% / 8.12% |
LoseAPVO / S&P APVO unavailable / 14.29% |
| 2018-Q41/3 |
LoseAPVO / S&P -75.00% / -13.52% |
WinAPVO / S&P 57.37% / 9.05% |
LoseAPVO / S&P APVO unavailable / 18.23% |
| 2018-Q31/3 |
LoseAPVO / S&P 1.80% / 7.71% |
WinAPVO / S&P 33.63% / 10.21% |
LoseAPVO / S&P APVO unavailable / 19.06% |
| 2018-Q22/3 |
WinAPVO / S&P 52.60% / 3.43% |
WinAPVO / S&P 76.52% / 9.03% |
LoseAPVO / S&P APVO unavailable / 14.46% |
| 2018-Q10/3 |
LoseAPVO / S&P -22.88% / -0.76% |
LoseAPVO / S&P -7.51% / 7.68% |
LoseAPVO / S&P APVO unavailable / 12.46% |
| 2017-Q41/3 |
WinAPVO / S&P 85.15% / 6.64% |
LoseAPVO / S&P -38.56% / 7.03% |
LoseAPVO / S&P APVO unavailable / 13.82% |
| 2017-Q31/3 |
WinAPVO / S&P 10.63% / 4.48% |
LoseAPVO / S&P -50.20% / 5.68% |
LoseAPVO / S&P APVO unavailable / 17.57% |
| 2017-Q20/3 |
LoseAPVO / S&P 0.49% / 3.09% |
LoseAPVO / S&P -65.97% / 4.83% |
LoseAPVO / S&P APVO unavailable / 17.74% |
| 2017-Q10/3 |
LoseAPVO / S&P -15.57% / 6.07% |
LoseAPVO / S&P APVO unavailable / 3.67% |
LoseAPVO / S&P APVO unavailable / 13.32% |
| 2016-Q40/3 |
LoseAPVO / S&P -4.69% / 3.82% |
LoseAPVO / S&P APVO unavailable / 2.09% |
LoseAPVO / S&P APVO unavailable / 7.05% |
| 2016-Q30/3 |
LoseAPVO / S&P APVO unavailable / 3.85% |
LoseAPVO / S&P APVO unavailable / 0.20% |
LoseAPVO / S&P APVO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | APVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.80% | 20.78% |
| Annualized return | -91.80% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | APVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -95.32% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | APVO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -79.83% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |